Is CVSA a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Nursing demand and the Chamberlain pipeline, with revenue (fy2026) at ~$1.95 billion, up ~9.3%. The bear case rests on the dominant risk is federal policy rather than competition. Analysts covering it are spread from $140.00 to $175.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The dominant risk is federal policy rather than competition. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $140.00, +13.8% from the $122.97 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Nursing demand and the Chamberlain pipeline. Chamberlain is the nursing school and the largest segment, with ~39,500 students at the end of fiscal 2026, up ~1.6%. The most optimistic analyst target on CVSA is $175.00, +42.3% from the $122.97 price. That figure is only reachable if this thesis works close to its best case.

The dominant risk is federal policy rather than competition. Grad PLUS loans ended for new borrowers on 1 July 2026 and most graduate students are now capped at ~$20,500 a year and ~$100,000 lifetime, which is below the full cost of several Walden doctoral pathways and could slow the segment that has been driving enrollment growth; fiscal 2027 revenue guidance of ~5% to ~7% growth already implies a slowdown, and analysts expect the December 2026 quarter's EPS to be roughly flat to slightly lower year over year. The wider Title IV rules matter too: the 90/10 revenue test, gainful employment metrics and accreditation reviews all apply, and a change to any of them affects the whole revenue base. The company also carries a reputational and litigation history, including a ~$28.5 million class action settlement over Walden's DBA program that received final court approval in October 2024, and consumer advocacy groups have continued to criticize the institutions after the rebrand. Operationally, Chamberlain enrollment growth has been low single digits (~1.6% in fiscal Q4 2026), and the gap between adjusted EPS (~$8.25) and GAAP EPS (~$7.04) for fiscal 2026 is worth checking in the filings. The shares are still down ~14% over one year despite the 2026 rebound, and some research outlets have flagged the stock as one to avoid. The most pessimistic published target is $140.00, +13.8% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Covista Inc.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Nursing demand and the Chamberlain pipeline) stalling in the reported numbers rather than in the narrative, the risk above (the dominant risk is federal policy rather than competition) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

CVSA is Covista Inc., the same company that traded as Adtalem Global Education under ATGE. The name change was announced on 5 February 2026 and the ticker changed to CVSA on the New York Stock Exchange on 24 February 2026. It is a rename, not a merger or spin-off, so existing shareholders simply saw the symbol change.

It operates five accredited institutions that train healthcare workers: Chamberlain University (nursing), Walden University (online graduate degrees) and, in the Medical and Veterinary segment, American University of the Caribbean School of Medicine, Ross University School of Medicine and Ross University School of Veterinary Medicine. Total enrollment passed 100,000 students in the March 2026 quarter and stood at ~99,500 at the end of June 2026.

Almost all revenue is tuition and fees paid by students, a large share of which is funded by federal Title IV student aid. Revenue is reported in three segments: Chamberlain at ~$197 million, Walden at ~$187 million and Medical and Veterinary at ~$103.5 million in fiscal Q3 2026. Costs are largely faculty, marketing and campus or platform expense, which is why margins expand as online enrollment scales.